TY - JOUR
T1 - Breast cancer, version 4.2021 featured updates to the NCCN guidelines
AU - Gradishar, William J.
AU - Moran, Meena S.
AU - Abraham, Jame
AU - Aft, Rebecca
AU - Agnese, Doreen
AU - Allison, Kimberly H.
AU - Blair, Sarah L.
AU - Burstein, Harold J.
AU - Dang, Chau
AU - Elias, Anthony D.
AU - Giordano, Sharon H.
AU - Goetz, Matthew P.
AU - Goldstein, Lori J.
AU - Hurvitz, Sara A.
AU - Isakoff, Steven J.
AU - Jankowitz, Rachel C.
AU - Javid, Sara H.
AU - Krishnamurthy, Jairam
AU - Leitch, Marilyn
AU - Lyons, Janice
AU - Matro, Jennifer
AU - Mayer, Ingrid A.
AU - Mortimer, Joanne
AU - O'Regan, Ruth M.
AU - Patel, Sameer A.
AU - Pierce, Lori J.
AU - Rugo, Hope S.
AU - Sitapati, Amy
AU - Smith, Karen Lisa
AU - Smith, Mary Lou
AU - Soliman, Hatem
AU - Stringer-Reasor, Erica M.
AU - Telli, Melinda L.
AU - Ward, John H.
AU - Wisinski, Kari B.
AU - Young, Jessica S.
AU - Burns, Jennifer L.
AU - Kumar, Rashmi
N1 - Publisher Copyright:
© 2021 Harborside Press. All rights reserved.
PY - 2021/5
Y1 - 2021/5
N2 - The NCCN Guidelines for Breast Cancer include up-to-date guidelines for clinical management of patients with carcinoma in situ, invasive breast cancer, Paget disease, phyllodes tumor, inflammatory breast cancer, male breast cancer, and breast cancer during pregnancy. These guidelines are developed by a multidisciplinary panel of representatives from NCCN Member Institutions with breast cancer-focused expertise in the fields of medical oncology, surgical oncology, radiation oncology, pathology, reconstructive surgery, and patient advocacy. These NCCN Guidelines Insights focus on the most recent updates to recommendations for adjuvant systemic therapy in patients with nonmetastatic, early-stage, hormone receptor-positive, HER2-negative breast cancer.
AB - The NCCN Guidelines for Breast Cancer include up-to-date guidelines for clinical management of patients with carcinoma in situ, invasive breast cancer, Paget disease, phyllodes tumor, inflammatory breast cancer, male breast cancer, and breast cancer during pregnancy. These guidelines are developed by a multidisciplinary panel of representatives from NCCN Member Institutions with breast cancer-focused expertise in the fields of medical oncology, surgical oncology, radiation oncology, pathology, reconstructive surgery, and patient advocacy. These NCCN Guidelines Insights focus on the most recent updates to recommendations for adjuvant systemic therapy in patients with nonmetastatic, early-stage, hormone receptor-positive, HER2-negative breast cancer.
UR - http://www.scopus.com/inward/record.url?scp=85106923703&partnerID=8YFLogxK
U2 - 10.6004/jnccn.2021.0023
DO - 10.6004/jnccn.2021.0023
M3 - Article
C2 - 34030128
AN - SCOPUS:85106923703
SN - 1540-1405
VL - 19
SP - 484
EP - 494
JO - JNCCN Journal of the National Comprehensive Cancer Network
JF - JNCCN Journal of the National Comprehensive Cancer Network
IS - 5
ER -